Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors

Abstract

CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients, but there still have not been any standardized systems for evaluating the antitumor efficacy yet. The WHO and RECIST criteria have already been established for a few years but not sufficient to fully characterize the activity of immunotherapy. Based on these two criteria, the irRC was proposed for evaluating the efficacy of immunotherapy. A variety of bioassays for immune monitoring including the specific and non-specific methods, have been established. We recommend detect levels of various immunocytes, immune molecules and soluble molecules to find the correlations among them and clinicopathological characteristics to establish criteria for immunological classification. We also recommend a paradigm shift for the oncologists in the evaluation of immune therapies to ensure assessment of activity based on clinically relevant criteria and time points.

DOI: 10.1186/s12967-014-0215-0

Extracted Key Phrases

02004002014201520162017
Citations per Year

280 Citations

Semantic Scholar estimates that this publication has 280 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Li2014EvaluationOT, title={Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors}, author={Xiaodong Li and Mei Qing Ji and Xiao Zheng and Zhong-hua Ning and Jun Wu and Binfeng Lu and Chang-ping Wu and Jing-ting Jiang}, booktitle={Journal of Translational Medicine}, year={2014} }